InsiderStreet Equity Research

Produced by InsiderStreet.ai from live production data. It is not investment advice, not an offer or solicitation to buy or sell any security, and not a recommendation for any investor. Do not rely on it for any investment decision.

Last Close

$44.39

2026-10-16

Market Cap

$64.3B

Volume

12.4M

52-Wk High

$105.65

52-Wk Low

$41.39

Trailing PE

17.9

P/S

3.06

Gross Margin

71.2%

Net Margin

17.5%

ROE

15%

ROIC

11%

Piotroski

8/9

Altman Z

3.0

1-Yr Return

-54.6%

5-Yr Return

+4.4%

Boston Scientific Corporation (BSX) operates as a global leader in medical technology, specializing in the design, manufacturing, and commercialization of innovative medical devices tailored for a diverse array of interventional medical specialties across the globe. Its business is strategically organized into three principal segments: MedSurg, Rhythm and Neuro, and Cardiovascular. Within these divisions, the company provides a comprehensive portfolio of solutions addressing various gastrointestinal and pulmonary ailments, as well as urological and pelvic health concerns. This extends to advanced implantable devices for managing cardiac rhythm disorders, such as cardioverter-defibrillators, cardiac resynchronization therapy devices, and pacemakers, complemented by remote patient management systems. Furthermore, Boston Scientific offers sophisticated technologies for diagnosing and treating complex heart rate and rhythm irregularities. These encompass 3-D cardiac mapping and navigation tools, along with a suite of specialized catheters (including ablation, diagnostic, mapping, and intracardiac ultrasound types), delivery sheaths, and related accessories. Its offerings also extend to neurological conditions, providing spinal cord stimulator systems for chronic pain management, indirect decompression systems, and deep brain stimulation systems. In the realm of interventional cardiology, the company's innovations include drug-eluting coronary stent systems designed for treating coronary artery disease, products for percutaneous coronary interventions to combat atherosclerosis, and intravascular imaging catheters (such as ultrasound and fractional flow reserve devices) for assessing coronary arteries, heart chambers, and peripheral vessels. It also develops structural heart therapies. Beyond this, Boston Scientific supplies an array of stents, balloon catheters, wires, and atherectomy systems for the treatment of arterial diseases. For venous conditions, it provides thrombectomy and acoustic pulse thrombolysis systems, alongside wires and stents. Critically, the company also contributes to cancer treatment through peripheral embolization devices, radioactive microspheres, various ablation systems (including cryotherapy), and micro and drainage catheters. The organization was established in 1979 and maintains its corporate headquarters in Marlborough, Massachusetts.

SectorHealthcareIndustryMedical - DevicesExchangeNYSEMarket Cap$64.3BEmployees59,000 (SEC-filed)CEOMichael F. MahoneyIPO1992-05-19CountryUS

300 Boston Scientific Way, Marlborough, MA 01752-1234 · Tel 508 683 4000 · bostonscientific.com

INSIDERSTREET SCORE67 / 100Street mean $60.11 (19 analysts, last qtr) — their number, not ours

INSIDER CONSENSUS SIGNALNET BUYING$10.0M open-market purchases vs $0.0M sales / 6 mo

1 Year vs S&P 500 · BSX -54.6% · S&P 500 +15.9% · spread -70.5pp

7 Years vs S&P 500 · BSX +4.4% · S&P 500 +189.9% · spread -185.4pp

Both charts indexed to 100 at the start of their window and drawn on a single shared scale, so the gap to the benchmark is the gap you see. Adjusted closes throughout.

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

INSIDERSTREET
SCORE67of 100

Score Breakdown

Profitability	67/100
Growth	68/100
Momentum	93/100
Quality	84/100
Earnings Quality	81/100
Balance Sheet	61/100
Value	50/100
Risk (safety)	65/100
Overall	66.6/100

Each component is a diagnostic reading on its own 0-100 scale. The overall score is computed separately from the underlying financials and is not the average of the rows above — components are not equally weighted and three of them (Momentum, Value, Risk) are derived partly from price rather than from the business.

Peer Comparison — IS Score

Symbol	IS Score
EW	65
SYK	74
MDT	64
DXCM	81
ABT	57
ZBH	60
BSX	67

IS Score Trend — quarterly

14 quarters, 23 Q1 to 26 Q2. Peak 74 in 25 Q3, latest 67 — -7 since. Fell in 2 of the last 4 quarters. Dashed line marks 40 on the 0-100 scale.

BUSINESS QUALITY67 / 100IS Score 66.6 / 100 · -6.9 from peak of 74

Fundamental factor model, quarterly. Measures how the business is doing - not where the price is going.

PRICE STRUCTURELEAN BULLISHTechnical Score 56 / 100 · Power +11 · 15 of 22 indicator votes bullish

Vote share across trend, momentum, volume, volatility and pattern families. Describes where the price is, not where it is going.

Both readings sit above the midpoint — business quality at 67 and price structure at 56 out of 100 — so they are not in conflict. The fundamentals and the tape are saying the same thing, which is the case in which either one alone would have been enough.

Trigger	Where it stands now	What it would mean
IS Score reaches 75 and holds two consecutive quarters	now 66.6	would move us up one band
IS Score stops falling - one quarter higher than the prior	last four: 74 → 72 → 73 → 67	the direction matters more than the level
Technical vote share back above 50%	now 55%	price structure no longer broken
Institutional holder count rises two quarters running	peak 1,795 → now 1,490	fewer institutions willing to hold is our clearest warning

We publish these so the view can be shown to be wrong. If none of them move and our reading does, we owe you an explanation.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

This page is InsiderStreet's own reading, produced from the data in the rest of this document. It is not a price target and not investment advice. Analyst consensus and street price targets appear later under their own heading and are the street's numbers, not ours.

Site Convergence Score3 of 4top 4% of 29,420 symbols

Sources Aligned— of 3independent disclosures

Congress (180d)15 buys2026-08-18

Insider Buys (180d)10$10.04M

ETF Funds (30d)1222 up / 1070 downnet +152 funds

Congressional and insider figures are disclosed purchases in the trailing 180 days; ETF figures are COUNTS OF FUNDS whose holding changed in 30 days, not dollars. Coincidence of separate disclosures, not coordination. An absent source means nothing qualifying was disclosed in its window.

Institutions holding — 12 quarters

Peak 1,795 · latest 1,490 (-305 from peak).

Quarter	Holders	13F shares	Value	Reported own%
2026 Q2	1,490	1339.1M	$56.9B	90.6%
2026 Q1	1,680	1341.0M	$83.2B	90.8%
2025 Q4	1,795	1365.0M	$127.4B	92.4%
2025 Q3	1,717	1343.9M	$129.2B	91.0%
2025 Q2	1,699	1354.9M	$142.5B	91.7%
2025 Q1	1,652	1343.2M	$133.0B	90.9%
2024 Q4	1,524	1341.4M	$118.0B	90.8%
2024 Q3	1,404	1324.7M	$109.3B	89.7%
2024 Q2	1,329	1328.1M	$100.3B	89.9%
2024 Q1	1,234	1327.9M	$89.3B	89.9%
2023 Q4	1,155	1336.3M	$76.0B	90.4%
2023 Q3	1,062	1337.9M	$69.4B	90.5%

How to read ownership above 100%. A 13F reports the positions a manager has investment discretion over, and where two or more managers share discretion over the same block, each one reports it. Summed across filers, the total can therefore exceed the shares actually outstanding without anything being wrong. We publish the figure as filed rather than netting it down, and flag separately any quarter where the arithmetic is not merely high but impossible.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Insider	Role	Date	Type	Shares	Value	Post-Txn Owned
O'Connor Padraig Andrew	EVP, Global Operations	2026-09-02	EXERCISE	1,171	—	8,459
O'Connor Padraig Andrew	EVP, Global Operations	2026-09-02	TAX W/H	567	$0.03M	7,892
O'Connor Padraig Andrew	EVP, Global Operations	2026-09-02	EXERCISE	1,171	—	3,516
Morano Susan E	director	2026-08-25	BUY	2,040	$0.10M	13,784
Woodworth Emily	SVP, Global Controller and CAO	2026-08-11	I-Discretionary	2,930	$0.15M	2,930
Monson Jonathan	EVP and CFO	2026-08-10	I-Discretionary	9,908	$0.50M	9,908
Habiger David C	director	2026-08-05	BUY	2,100	$0.10M	17,160
Habiger David C	director	2026-08-04	BUY	140	$0.01M	15,060

6-mo decomposition (Form 4)	Txns	Shares	Value	Signal weight
P — Open-market purchases	10	206,362	$10.0M	Counted
M — Exercises (paired A/D)	5	8,000	—	None — mechanics
F — Tax withholding	5	3,828	$0.2M	None — compensation
G — Gifts	1	386,755	—	None

Monthly Net Insider Flow (000 shares)

Net of acquisitions minus dispositions, all Form 4 types.

Signal Summary

SignalNet Buying

Open-Market Sells$0.0M0 txns / 6 mo

Open-Market Buys$10.0M10 txns / 6 mo

ClusterNone active3+ insiders / 21 days

Filed	Filer	Shares registered	Est. proceeds
2026-02-02	Michael F Mahoney	160,901	$15.0M
2025-12-01	Arthur C Butcher	17,313	$1.8M
2025-11-06	Zane Ellen M	2,901	$0.3M
2025-11-03	Joseph M Fitzgerald	50,000	$5.0M
Trailing 12 mo	8 filings	344,006	$34M

Filed	Form	Reporting person	% of class	Shares
2026-08-06	SCHEDULE 13G/A	Abigail P. Johnson	3.10%	46.4M sh
2026-05-06	SCHEDULE 13G/A	Abigail P. Johnson	5.10%	75.8M sh
2026-04-29	SCHEDULE 13G	Vanguard Capital Management	7.47%	111.1M sh
2026-03-26	SCHEDULE 13G/A	The Vanguard Group	—	exit/reporting change

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Member	Chamber	Trade	Size band	Traded	Disclosed
Ro Khanna	House	SELL	$1,001 - $15,000	2026-09-11	2026-10-09
Kevin Hern	House	SELL	$50,001 - $100,000	2026-09-09	2026-09-28
Kevin Hern	House	SELL	$50,001 - $100,000	2026-09-09	2026-09-25
John Boozman	Senate	SELL	$1,001 - $15,000	2026-06-04	2026-07-13
Markwayne Mullin	Senate	BUY	$15,001 - $50,000	2025-12-29	2026-01-16
Markwayne Mullin	Senate	BUY	$15,001 - $50,000	2025-12-29	2026-01-15

House 12-Mo58 trades27 purchases

Senate 12-Mo5 trades2 purchases

CoverageSTOCK Act filings30-45 day disclosure lag

13F Filers (last complete Q)1,680

13F Shares1.34B90.8% of shares out

New / Closed197 / 281positions, QoQ

Increased / Reduced675 / 639positions, QoQ

Put/Call (13F)0.74option positions

Free Float99.7%1.44B sh

2.8 · Largest Reporting 13F Managers

Manager	Shares	Value
Assenagon Asset Management S.A.	6.7M	$294M
Zwj Investment Counsel Inc	739,647	$32M
Vontobel Holding Ltd.	587,308	$26M
Gateway Investment Advisers Llc	505,049	$22M
Gradient Investments Llc	443,592	$19M
Mn Services Vermogensbeheer B.V.	433,013	$19M

EDGAR 13F holdings as of 2026-09-30; filer values normalized to dollars.

2.9 · Top ETF & Fund Ownership

Fund	Weight	Position
VITSX	0.1%	$2.0B
VTSAX	0.1%	$2.0B
VSMPX	0.1%	$2.0B
VTI	0.1%	$2.0B
VFINX	0.1%	$1.7B
VOO	0.1%	$1.7B

13F Filers Holding BSX — quarterly

Institutional Put/Call — quarterly

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Daily short-sale volume as % of volume reported in FINRA's short-sale file — a flow measure, not short interest; dashed = 50-day average.

Latest Session34.1%2026-10-15

20-Day Avg43.1%50-day 45.0%

TrendFalling20d vs 50d

By Market CenterQ: 34% · N: 40% · B: 24%latest session

Weekly Notional ($B)

Where BSX Trades in the Dark

ATS Venue (4-wk)	Shares	Avg trade
Incr Intelligent Cross Llc	17.1M	89 sh
Ubsa Ubs Ats	15.0M	89 sh
Ebxl Level Ats	11.3M	70 sh
Pure Purestream	10.5M	63 sh
Sgmt Sigma X2	10.0M	95 sh
Bids Bids Ats	9.7M	641 sh

Where a dollar of Boston Scientific Corporation revenue goes. All values FY2025 filings, live.

Region	Revenue	Share
UNITED STATES	$12.9B	64%
Non-US	$7.2B	36%

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

BSX (live moat model)Peer median: EW · SYK · MDT · DXCM · ABT

Component scores from the live moat model. Peer median illustrative.

Moat score 64/100 — Narrow; primary source Network Effects.

3.8 · Employees (SEC filings)

Officer	Title
Michael F. Mahoney	Chairman, President & Chief Executive Officer
Joseph Fitzgerald	Executive VP & Group President of Cardiovascular
Arthur Crosswell Butcher	Executive Vice President and Group President of MedSurg & Asia Pacific
Vance R. Brown	EVP, General Counsel & Corporate Secretary

Revenue ($B)

EPS ($) — GAAP diluted actual, street-basis estimate

Actual bars are GAAP diluted EPS from the filed income statement; the lighter forward bars are street-basis consensus. The two are different measures and are not comparable quarter to quarter.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Quarterly EPS — Actual vs. Consensus

Beats (>2%)5 of 6recent quarters

Avg Surprise+4.5%

Next Report2026-10-28

Income Quality1.23OCF ÷ net income

Beat Rate—%0 of 0 quarters

Current Streak0longest 0

Avg EPS Surprise—%median —%

Surprise Trend—last 4 vs prior 4

Period	EPS est.	EPS actual	EPS surprise	Rev est. ($M)	Rev actual ($M)	Rev surprise

Announcement dates to . Consensus as it stood at each report. Revenue surprise shown where both estimate and actual are filed. A beat record is history, not a forecast.

Profit Margins (%)

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Revenue by Segment — Stacked

Live segmentation data.

YoY Growth Heatmap — Income Lines

YoY growth	FY21	FY22	FY23	FY24	FY25
Revenue	+19.9%	+6.7%	+12.3%	+17.6%	+19.9%
Gross profit	+33.8%	+3.4%	+14.5%	+16.3%	+34.9%
Operating income	+219.8%	-5.1%	+19.6%	+20.8%	+50.7%
Net income	-1368.3%	-32.9%	+128.2%	+16.4%	+55.7%

$B · FY ends	FY21	FY22	FY23	FY24	FY25
Revenue	11.9	12.7	14.2	16.7	20.1
Cost of revenue	4.4	5.0	5.4	6.5	6.2
Gross profit	7.5	7.7	8.8	10.3	13.9
R&D expense	1.2	1.3	1.4	1.6	2.1
SG&A expense	4.3	4.5	5.2	6.0	6.9
Operating income	1.9	1.8	2.2	2.6	4.0
EBITDA	2.5	2.7	3.5	3.9	3.7
D&A	1.1	1.1	1.2	1.3	0.0
Pretax income	1.1	1.1	2.0	2.3	3.4
Income tax	0.0	0.4	0.4	0.4	0.5
Net income	1.0	0.7	1.6	1.9	2.9
Diluted EPS ($)	0.69	0.45	1.07	1.25	1.94
Diluted shares (M)	1,434	1,440	1,464	1,486	1,494

Operating CF$5B

CapEx$1B

Free cash flow$4B

SBC$0B

Buybacks$0B

Net cash change$2B

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Balance Sheet — Full

$B	FY22	FY23	FY24	FY25
Cash & equivalents	0.9	0.9	0.4	2.0
ST investments	0.0	0.0	0.0	0.0
Receivables (net)	2.0	2.2	2.6	2.9
Total current assets	5.8	6.5	6.9	8.8
PP&E (net)	2.8	3.3	3.7	4.5
Goodwill + intangibles	18.8	20.4	23.8	25.3
Total assets	32.5	35.1	39.4	43.7
Accounts payable	0.9	0.9	1.0	1.1
Short-term debt	0.0	0.5	1.8	0.4
Deferred revenue	0.2	0.3	0.3	0.3
Total current liabilities	3.8	4.9	6.4	5.4
Long-term debt	8.9	8.6	8.8	11.5
Total liabilities	14.9	15.6	17.4	19.2
Shareholders' equity	17.6	19.5	22.0	24.5

Cash Flow Statement — Full

$B	FY22	FY23	FY24	FY25
Net income	0.7	1.6	1.8	2.9
D&A	1.1	1.2	1.3	1.4
Stock-based compensation	0.2	0.2	0.3	0.3
Working capital change	(1.0)	(0.8)	(0.5)	(0.2)
Operating cash flow	1.5	2.5	3.4	4.5
Capital expenditures	(0.6)	(0.8)	(0.8)	(0.9)
Investing cash flow	(2.0)	(2.6)	(5.7)	(2.6)
Buybacks	0.1	0.0	0.0	0.0
Dividends paid	(0.1)	(0.0)	0.0	0.0
Debt issuance / (repay)	(0.2)	(0.0)	1.8	(0.5)
Financing cash flow	(0.5)	0.0	1.8	(0.4)
Free cash flow	0.9	1.7	2.6	3.7

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Balance Sheet Structure ($B)

Cash Generation vs Capex ($B)

Left: what the balance sheet is made of — the gap between the assets bar and the liabilities bar is book equity. Right: whether the capex bar is covered by the operating-cash bar; where it is not, the difference was funded externally and free cash flow goes negative.

Ratio	FY21	FY22	FY23	FY24	FY25	TTM
PROFITABILITY
ROE	6.5%	4.1%	8.6%	9.0%	12.6%	15%
ROA	3.3%	2.2%	4.7%	5.0%	7.0%	8.1%
ROIC	7.1%	4.4%	6.3%	6.6%	9.8%	10.6%
Gross margin	62.8%	60.8%	62.0%	61.3%	69.0%	71.2%
Operating margin	16.2%	14.4%	15.3%	15.7%	19.8%	21.5%
Net margin	8.7%	5.5%	11.2%	11.1%	14.4%	17.5%
EBITDA margin	21.2%	21.6%	24.2%	23.5%	18.6%	27.6%
FCF margin	11.1%	7.2%	12.0%	14.6%	18.1%	—
VALUATION
P/E	58.66	95.48	53.63	71.83	49.35	17.9
P/B	3.67	3.80	4.43	6.11	5.89	2.6
P/S	5.13	5.26	6.00	7.95	7.10	3.06
P/FCF	46.36	72.70	50.13	54.60	39.34	17.7
EV/EBITDA	27.19	27.14	27.23	36.65	29.02	13.2
EV/Revenue	5.77	5.92	6.60	8.59	7.62	3.6
Earnings yield	1.7%	1.0%	1.9%	1.4%	2.0%	5.59%
FCF yield	2.2%	1.4%	2.0%	1.8%	2.5%	5.63%

Ratio	FY21	FY22	FY23	FY24	FY25	TTM
LEVERAGE & SOLVENCY
Current ratio	1.48	1.51	1.32	1.08	1.62	1.24
Quick ratio	1.10	1.02	0.82	0.64	1.08	0.74
Debt / equity	0.57	0.53	0.49	0.51	0.51	0.51
Debt / assets	29.3%	28.6%	27.0%	28.3%	28.4%	27.9%
Net debt / EBITDA	2.99	3.02	2.50	2.73	1.97	2.08
Interest coverage	4.07	3.34	8.29	7.08	11.03	—

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Ratio	FY21	FY22	FY23	FY24	FY25	TTM
EFFICIENCY
Asset turnover	0.38	0.39	0.42	0.45	0.48	0.46
Receivables turnover	7.19	6.77	6.78	7.00	7.32	6.9
DSO (days)	51	54	54	52	50	53
DPO (days)	53	61	61	54	62	74
Cash conversion cycle	118	121	140	148	157	174
GROWTH (YoY)
Revenue growth	19.9%	6.7%	12.3%	17.6%	19.9%	—
Net income growth	848.2%	-32.8%	127.8%	16.4%	56.0%	—
EPS growth	850.5%	-33.1%	122.4%	15.4%	55.4%	—
FCF growth	31.3%	-30.2%	85.5%	43.2%	48.7%	—
PER SHARE ($)
EPS (diluted, TTM)	0.72	0.48	1.08	1.24	1.93	2.48
Book value / share	11.57	12.18	13.06	14.61	16.20	17.04
Revenue / share	8.28	8.79	9.64	11.24	13.42	14.21
FCF / share	0.92	0.64	1.15	1.64	2.42	2.45
Cash / share	1.34	0.64	0.59	0.28	1.37	0.36
SHAREHOLDER RETURN & SCORES
Buyback yield	0.0%	0.1%	0.0%	0.1%	0.0%	3.16%
Altman Z-Score	2.88	3.28	3.99	5.35	5.48	3.0
Piotroski F-Score	8	6	7	5	7	8/9
Beneish M-Score	-2.48	-2.47	-2.49	-2.45	-2.62	-2.49

Model	Score	Zone	Note
Piotroski F-Score	8 / 9	Strong
Altman Z-Score	3.0	Safe (>2.99)	Grey
Income quality	1.23	Cash-backed	OCF ÷ net income
Beneish M-Score	-2.49	Non-manipulator	vs −2.22 threshold

DuPont Decomposition (TTM)	Value
Tax burden	0.95
Interest burden	0.88
Operating margin	20.9%
Asset turnover	0.48×
Financial leverage	1.83×
= ROE	15%

Growth Quality (live)	Value
Revenue stability	0.95
Earnings stability	0.92
Earnings persistence	0.81
Revenue CAGR 3y	16.1%
EPS CAGR 3y	58.0%
FCF CAGR 3y	36.5%

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Buyback Yield3.16%

Dividend Yield0.00%none paid

Total Shareholder Return2.81%cash yield

SBC / Revenue0.8%dilution pressure

Company	Mkt cap	P/E	ROE	Net margin	Rev growth	Piotroski	1-yr ret
EW	$49.9B	49.8	9%	13.9%	+14.6%	6/9	+19.2%
SYK	$113.0B	30.3	17%	19.4%	+8.5%	9/9	-20.2%
MDT	$121.2B	23.2	11%	15.1%	+9.8%	9/9	+3.0%
DXCM	$32.5B	33.2	38%	19.0%	+15.5%	9/9	+29.7%
ABT	$181.5B	33.7	11%	7.4%	+8.1%	5/9	—
ZBH	$18.1B	23.0	6%	9.1%	+8.6%	6/9	—
PEN	$12.6B	78.4	11%	8.9%	+17.6%	6/9	—
SNN	$12.2B	19.0	22%	9.8%	+11.5%	8/9	—

1-yr returns computed from adjusted price history; peers without a tracked series show —.

Buy

44 Analysts

Str Sell (0)Sell (0)Hold (7)Buy (36)Str Buy (1)

Mean Target (qtr)$60.1119 targets

Target vs. Price+35.4%last-quarter mean

Next Report2026-10-28street $0.75

Consensus estimates	Revenue mean	High / Low	EPS mean	High / Low	# EPS est.
FY2026	$21.19B	$21.72B / $20.87B	$3.25	$3.32 / $3.12	15
FY2027	$22.22B	$23.14B / $21.75B	$3.39	$3.60 / $3.22	15
FY2028	$23.67B	$24.81B / $22.92B	$3.74	$3.98 / $3.64	5

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Street Price Target — Trajectory

Window	Avg Target	vs. Price	# Targets
Last Month	$53.50	+20.5%	6
Last Quarter	$60.11	+35.4%	19
Last Year	$85.53	+92.7%	78
All Time	$83.24	+87.5%	149

Rolling mean of published targets vs. last close $44.39. Aggregated from StreetInsider, Benzinga, Pulse 2.0.

Third-Party Composite Rating

A-

DCF

5/5

ROE

4/5

ROA

5/5

Debt/Eq

1/5

P/E

3/5

P/B

3/5

Independent quant composite as of 2026-10-16; components scored 1–5 (5 best). Shown for contrast with the InsiderStreet Score — methodologies differ.

BSX -54.6% vs S&P 500 +15.9% — spread -70.5pp

Sector — XLV +24.2%

Peer Set — indexed to 100

All series indexed to 100 at the start of the window, adjusted closes.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Candlesticks with SMA 20/50 overlay, Bollinger (20,2σ) band, volume, and Wilder RSI(14) — computed from live daily OHLCV.

Moving Average	Value	Distance	% Distance	Signal
SMA 20	$43.45	+0.94	+2.16%	Above
SMA 50	$46.09	-1.70	-3.69%	Below
SMA 200	$59.10	-14.71	-24.89%	Below
EMA 9	$43.46	+0.93	+2.14%	Above
EMA 21	$43.71	+0.68	+1.56%	Above
EMA 50	$45.10	-0.71	-1.57%	Below
EMA 200	$58.19	-13.80	-23.72%	Below

Series and readings from the nightly technical-indicator history — identical data to the site's ribbon chart. Supertrend segments colored by direction.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

TECHNICAL VERDICTLEAN BULLISHPower Score +1115 of 22 indicator votes bullish

Family Scores (site weights)

Trend 30%44

Momentum 25%90

Volume 20%44

Volatility 10%33

Patterns 15%50

This Week55% bullishof 11 price-based votes

4 Weeks Ago0%+55 pts since

12 Weeks Ago0%+55 pts since

ReadImprovingweek-over-week trajectory

Price vs SMA 20$43.45

Price vs SMA 50$46.09

Price vs SMA 200$59.10

EMA 9/21 Cross43.5/43.7

SMA 50/200Death

ADX DirectionADX 17

Supertrend$45

Parabolic SAR$42

SMA Slope0.050

RSI52.5

Stochastic K/D75/63

StochRSI K/D91/87

Williams %R-13

CCI88

TSI vs Signal-12.0

CMO5.0

ROC4.20%

OBV SignalDistrib

Chaikin MF0.140

MFI42

Force Index2M

Elder Ray Bull1.12

RSI (14)30 oversold · 70 overbought

Stochastic %Kvs %D 63

Money Flowvolume-weighted RSI

ADXtrend strength · <20 weak

Williams %Rinverted scale

Level	Value	Level	Value
Pivot / R1 / R2	$44.01 / $44.56 / $44.98	S1 / S2	$43.59 / $43.04
Bollinger (20,2)	$41.59 – $45.30	Squeeze	Off
52-wk range	$41.39 – $105.65	Off 52-wk high	-58.0%
ATR (14)	$1.25 (2.8%)	Historical vol	22.4%

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

+6.2%Jan70%

-1.9%Feb55%

+0.2%Mar52%

+3.4%Apr70%

+1.1%May55%

-0.5%Jun45%

+0.2%Jul45%

+1.2%Aug60%

-0.9%Sep40%

-1.4%Oct40%

-1.2%Nov50%

+3.3%Dec65%

Sample: 20 years — treat short histories as suggestive, not statistical.

Computed from live weekly prices	BSX	S&P 500
Weekly volatility (σ, 1y)	5.79%	1.83%
Best / worst week (1y)	+9.7% / -19.5%	—
Max drawdown (5y, monthly)	-59.1%	—
1-week VaR (95%)	-13.3%	—
Beta (5y)	0.57	1.00

BSX EQUITY WEATHER (LIVE)RAINY · -25

Trend-41

Momentum+29

Volume-42

Volatility-60

Breadth-30

MARKET REGIME (2026-10-16)NEUTRAL

VIX19.99Normal

Dow TheoryConfirmed Bearish

SPY / QQQ TSI7.2 / 4.7trend strength

Sector Strength46/100breadth average

Average sentiment of 390 stories, weekly buckets, −1 to +1.

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Overall-25.4-5.2 vs industry

Trend-41.0-18.9 vs industry

Momentum+29.5+51.5 vs industry

Volume-42.4-37.4 vs industry

Reading	BSX	Medical - Devices n=524	Healthcare n=5,272	All US symbols n=70,435
Overall	-25.4	-20.2	-24.0	-20.5
Trend	-41.0	-22.1	-25.6	-21.3
Momentum	+29.5	-22.0	-28.5	-15.8
Volume	-42.4	-5.0	-25.0	-3.8

Trend, momentum and volume are computed per company. Volatility and breadth are market-regime values shared by every symbol in the universe, so they are reported once under Market Regime rather than compared here - a company cannot differ from its sector on a constant.

Executive	Total comp	Structure
Michael F. Mahoney Chairman of the Board, Pr	$23.5M	75% equity+incentive
Joseph M. Fitzgerald Executive Vice Presiden	$8.0M	72% equity+incentive
Arthur C. Butcher Executive Vice President a	$6.5M	68% equity+incentive
Daniel J. Brennan Former Executive Vice Pres	$6.3M	72% equity+incentive
Jonathan R. Monson Executive Vice President	$6.1M	41% equity+incentive

Pillar (live disclosure scores)	Score
Environmental	73
Social	59
Governance	57
Composite ESG	63

Composite ESG Trend

Filed	8-K contents	Items
2026-10-07	Officer/Director Change; Other Events; Exhibits	5.02,8.01,9.01
2026-09-23	Officer/Director Change	5.02
2026-09-08	Other Events	8.01
2026-08-26	Other Events	8.01
2026-07-29	Earnings Release; Exhibits	2.02,9.01
2026-07-27	Exit/Disposal Costs	2.05
2026-05-18	Other Events; Exhibits	8.01,9.01
2026-05-18	Other Events; Exhibits	8.01,9.01

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Methodology. Every figure originates in InsiderStreet's production data layer and is computed deterministically by the same engines that power insiderstreet.ai. This factsheet contains no model-written text. Sections without underlying data are omitted rather than estimated.

DISCLOSURES. This document is produced by InsiderStreet.ai from live production data. It is not investment advice, not an offer or solicitation to buy or sell any security, and not a recommendation tailored to any person. Data is sourced as of the dates shown and may no longer be current. InsiderStreet.ai is not a registered investment adviser or broker-dealer. Investing involves risk, including loss of principal. Past performance does not guarantee future results. Do not make any investment decision based on this document. © 2026 InsiderStreet.ai — all rights reserved. Redistribution prohibited.

Data domain	Source	Coverage for this report
Price & volume	market_db.historical_prices	52 rows
Fundamentals	income_statements_annual	6 rows · 2020 to 2025
Reported vs consensus	fact/earnings_calendar	24 rows · 2020-10-28 to 2026-07-29
Analyst estimates	dim/forward_estimates	3 rows · 2026-12-31 to 2028-12-31
Institutional ownership (13F)	holdings_db.institutional_ownership_summary	114 rows · 1998 to 2026
Insider transactions (Form 4)	edgar/form4	12 rows · 2026-07-31 to 2026-09-02
Proposed sales (Form 144)	edgar/form144	1 record
Beneficial ownership (13D/G)	edgar/13dg	4 rows · 2026-03-26 to 2026-08-06
Short-sale volume (FINRA)	edgar/short_volume_daily	60 rows · 2026-07-23 to 2026-10-15
Dark pool (ATS, tier 1)	edgar/darkpool_weekly	12 rows · 2026-06-15 to 2026-08-31
ETF & fund holding	etf_holdings_changelog (30d)	1 record
Peer set	stock_peers_dynamic	8 rows
Industry medians	industry_medians	1 record
Congressional trades	congress_db (House + Senate)	1 record
ESG	fact/esg_disclosures	1 record

Method. Every figure in this factsheet is looked up from a named field computed in code. It contains no model-written text.

Not covered. Short interest as a percent of float and days-to-cover are not in this data set — the short-sale figures above are FINRA volume, a flow, and cannot support squeeze or covering analysis. Options positioning and intraday data are also absent. 13F ownership is filed 45 days after quarter end and congressional trades are disclosed on a lag, so both describe a past position, not a current one.